Literature DB >> 31059627

Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study.

Sinan Guloksuz1,2, Lotta-Katrin Pries1, Philippe Delespaul1, Gunter Kenis1, Jurjen J Luykx3,4,5, Bochao D Lin4, Alexander L Richards6, Berna Akdede7, Tolga Binbay7, Vesile Altınyazar8, Berna Yalınçetin9, Güvem Gümüş-Akay10, Burçin Cihan11, Haldun Soygür12, Halis Ulaş13, EylemŞahin Cankurtaran14, Semra Ulusoy Kaymak15, Marina M Mihaljevic16,17, Sanja Andric Petrovic17, Tijana Mirjanic18, Miguel Bernardo19,20,21, Bibiana Cabrera19,20,21, Julio Bobes21,22,23,24, Pilar A Saiz21,22,23,24, María Paz García-Portilla21,22,23,24, Julio Sanjuan21,25, Eduardo J Aguilar21,25, José Luis Santos21,26, Estela Jiménez-López21,27, Manuel Arrojo28, Angel Carracedo29, Gonzalo López21,30, Javier González-Peñas21,30, Mara Parellada21,30, Nadja P Maric16,17, Cem Atbaşog Lu31, Alp Ucok32, Köksal Alptekin7, Meram Can Saka31, Celso Arango21,30, Michael O'Donovan6, Bart P F Rutten1, Jim van Os1,3,33.   

Abstract

Schizophrenia is a heritable complex phenotype associated with a background risk involving multiple common genetic variants of small effect and a multitude of environmental exposures. Early twin and family studies using proxy-genetic liability measures suggest gene-environment interaction in the etiology of schizophrenia spectrum disorders, but the molecular evidence is scarce. Here, by analyzing the main and joint associations of polygenic risk score for schizophrenia (PRS-SCZ) and environmental exposures in 1,699 patients with a diagnosis of schizophrenia spectrum disorders and 1,542 unrelated controls with no lifetime history of a diagnosis of those disorders, we provide further evidence for gene-environment interaction in schizophrenia. Evidence was found for additive interaction of molecular genetic risk state for schizophrenia (binary mode of PRS-SCZ above 75% of the control distribution) with the presence of lifetime regular cannabis use and exposure to early-life adversities (sexual abuse, emotional abuse, emotional neglect, and bullying), but not with the presence of hearing impairment, season of birth (winter birth), and exposure to physical abuse or physical neglect in childhood. The sensitivity analyses replacing the a priori PRS-SCZ at 75% with alternative cut-points (50% and 25%) confirmed the additive interaction. Our results suggest that the etiopathogenesis of schizophrenia involves genetic underpinnings that act by making individuals more sensitive to the effects of some environmental exposures.
© 2019 World Psychiatric Association.

Entities:  

Keywords:  Schizophrenia; bullying; cannabis; childhood trauma; environment; gene-environment interaction; genetics; polygenic risk; psychosis

Year:  2019        PMID: 31059627      PMCID: PMC6502485          DOI: 10.1002/wps.20629

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  59 in total

1.  Cannabis-induced psychosis-like experiences are associated with high schizotypy.

Authors:  E J Barkus; J Stirling; R S Hopkins; S Lewis
Journal:  Psychopathology       Date:  2006-04-12       Impact factor: 1.944

2.  The long-term effects of coping strategy use in victims of bullying.

Authors:  Simon C Hunter; Joaquin Mora-Merchan; Rosario Ortega
Journal:  Span J Psychol       Date:  2004-05       Impact factor: 1.264

3.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

4.  The estimation of synergy or antagonism.

Authors:  K J Rothman
Journal:  Am J Epidemiol       Date:  1976-05       Impact factor: 4.897

5.  Lifetime prevalence of psychotic and bipolar I disorders in a general population.

Authors:  Jonna Perälä; Jaana Suvisaari; Samuli I Saarni; Kimmo Kuoppasalmi; Erkki Isometsä; Sami Pirkola; Timo Partonen; Annamari Tuulio-Henriksson; Jukka Hintikka; Tuula Kieseppä; Tommi Härkänen; Seppo Koskinen; Jouko Lönnqvist
Journal:  Arch Gen Psychiatry       Date:  2007-01

6.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.

Authors:  N C Andreasen; M Flaum; S Arndt
Journal:  Arch Gen Psychiatry       Date:  1992-08

7.  Childhood trauma, dissociation, and psychiatric comorbidity in patients with conversion disorder.

Authors:  Vedat Sar; Gamze Akyüz; Turgut Kundakçi; Emre Kiziltan; Orhan Dogan
Journal:  Am J Psychiatry       Date:  2004-12       Impact factor: 18.112

8.  Development and validation of a brief screening version of the Childhood Trauma Questionnaire.

Authors:  David P Bernstein; Judith A Stein; Michael D Newcomb; Edward Walker; David Pogge; Taruna Ahluvalia; John Stokes; Leonard Handelsman; Martha Medrano; David Desmond; William Zule
Journal:  Child Abuse Negl       Date:  2003-02

9.  Heritability estimates for psychotic disorders: the Maudsley twin psychosis series.

Authors:  A G Cardno; E J Marshall; B Coid; A M Macdonald; T R Ribchester; N J Davies; P Venturi; L A Jones; S W Lewis; P C Sham; I I Gottesman; A E Farmer; P McGuffin; A M Reveley; R M Murray
Journal:  Arch Gen Psychiatry       Date:  1999-02

Review 10.  A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia.

Authors:  Geoffrey Davies; Joy Welham; David Chant; E Fuller Torrey; John McGrath
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  41 in total

1.  The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Authors:  Mario Maj; Jim van Os; Marc De Hert; Wolfgang Gaebel; Silvana Galderisi; Michael F Green; Sinan Guloksuz; Philip D Harvey; Peter B Jones; Dolores Malaspina; Patrick McGorry; Jouko Miettunen; Robin M Murray; Keith H Nuechterlein; Victor Peralta; Graham Thornicroft; Ruud van Winkel; Joseph Ventura
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

2.  Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort.

Authors:  Sinan Guloksuz; Lotta-Katrin Pries; Margreet Ten Have; Ron de Graaf; Saskia van Dorsselaer; Boris Klingenberg; Maarten Bak; Bochao D Lin; Kristel R van Eijk; Philippe Delespaul; Therese van Amelsvoort; Jurjen J Luykx; Bart P F Rutten; Jim van Os
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

3.  Association of Recent Stressful Life Events With Mental and Physical Health in the Context of Genomic and Exposomic Liability for Schizophrenia.

Authors:  Lotta-Katrin Pries; Jim van Os; Margreet Ten Have; Ron de Graaf; Saskia van Dorsselaer; Maarten Bak; Bochao D Lin; Kristel R van Eijk; Gunter Kenis; Alexander Richards; Michael C O'Donovan; Jurjen J Luykx; Bart P F Rutten; Sinan Guloksuz
Journal:  JAMA Psychiatry       Date:  2020-12-01       Impact factor: 21.596

4.  Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study.

Authors:  Lotta-Katrin Pries; Agustin Lage-Castellanos; Philippe Delespaul; Gunter Kenis; Jurjen J Luykx; Bochao D Lin; Alexander L Richards; Berna Akdede; Tolga Binbay; Vesile Altinyazar; Berna Yalinçetin; Güvem Gümüş-Akay; Burçin Cihan; Haldun Soygür; Halis Ulaş; Eylem Şahin Cankurtaran; Semra Ulusoy Kaymak; Marina M Mihaljevic; Sanja Andric Petrovic; Tijana Mirjanic; Miguel Bernardo; Bibiana Cabrera; Julio Bobes; Pilar A Saiz; María Paz García-Portilla; Julio Sanjuan; Eduardo J Aguilar; José Luis Santos; Estela Jiménez-López; Manuel Arrojo; Angel Carracedo; Gonzalo López; Javier González-Peñas; Mara Parellada; Nadja P Maric; Cem Atbaşoğlu; Alp Ucok; Köksal Alptekin; Meram Can Saka; Celso Arango; Michael O'Donovan; Bart P F Rutten; Jim van Os; Sinan Guloksuz
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

Review 5.  Magnetoencephalography for Schizophrenia.

Authors:  J Christopher Edgar; Anika Guha; Gregory A Miller
Journal:  Neuroimaging Clin N Am       Date:  2020-04-09       Impact factor: 2.264

6.  Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort.

Authors:  Sergi Mas; Daniel Boloc; Natalia Rodríguez; Gisela Mezquida; Silvia Amoretti; Manuel J Cuesta; Javier González-Peñas; Alicia García-Alcón; Antonio Lobo; Ana González-Pinto; Iluminada Corripio; Eduard Vieta; Josefina Castro-Fornieles; Anna Mané; Jeronimo Saiz-Ruiz; Patricia Gassó; Miquel Bioque; Miquel Bernardo
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

7.  Individualized prediction of three- and six-year outcomes of psychosis in a longitudinal multicenter study: a machine learning approach.

Authors:  Jessica de Nijs; Thijs J Burger; Ronald J Janssen; Seyed Mostafa Kia; Daniël P J van Opstal; Mariken B de Koning; Lieuwe de Haan; Wiepke Cahn; Hugo G Schnack
Journal:  NPJ Schizophr       Date:  2021-07-02

8.  Need for Ethnic and Population Diversity in Psychosis Research.

Authors:  Carla Burkhard; Saba Cicek; Ran Barzilay; Rajiv Radhakrishnan; Sinan Guloksuz
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

9.  Adverse effects of heavy cannabis use: even plants can harm the brain.

Authors:  Lucia Sideli; Giulia Trotta; Edoardo Spinazzola; Caterina La Cascia; Marta Di Forti
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

10.  What makes the psychosis 'clinical high risk' state risky: psychosis itself or the co-presence of a non-psychotic disorder?

Authors:  Laila Hasmi; Lotta-Katrin Pries; Margreet Ten Have; Ron de Graaf; Saskia van Dorsselaer; Maarten Bak; Gunter Kenis; Alexander Richards; Bochao D Lin; Michael C O'Donovan; Jurjen J Luykx; Bart P F Rutten; Sinan Guloksuz; Jim van Os
Journal:  Epidemiol Psychiatr Sci       Date:  2021-07-06       Impact factor: 6.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.